Results of the clinical study using a reparixin-paclitaxel combination in HER-2 negative breast cancer may highlight the potential for the use of CXCR1/2 small molecule antagonists as a viable strategy for the treatment of cancer, most likely in combination with established chemotherapies. This evidence concerns the gene CXCR1 and cancer.